Navigation Links
Clinical Update - Debio 9902 SR in Alzheimer's Disease
Date:3/4/2008

Successful DSMB Review From Ongoing Phase II BRAINz Study

LAUSANNE, Switzerland, March 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced today that following a meeting of the independent Data Safety Monitoring Board (DSMB), the Company received a recommendation to continue its Phase II BRAINz study with Debio 9902 SR (sustained release) for the treatment of Alzheimer's disease (AD),without modification.

The DSMB's objective is to monitor the well being and safety of patients participating in a study and to review the safety data throughout its duration.

"This recommendation by the DSMB authorising Debiopharm to continue the BRAINz study confirms the safety profile of Debio 9902 SR" said David Wilkinson, from MARC, Moorgreen Hospital, Southampton, England and Principal Investigator in the United Kingdom, who presented this recommendation at the 10th International Hong Kong Springfield Symposium on Advances in Alzheimer Therapy.

About Debio 9902 SR

Debio 9902 SR is a novel AChE inhibitor which is administered once every 4 weeks. It is transformed non-enzymatically into its active compound, huperzine A (hup A). Hup A has been used in China for centuries to treat distinct disorders such as memory loss, schizophrenia and hypertension, and is widely used in North America and Europe as a food additive to enhance cognition and neuroprotection. The dual mode of action of Debio 9902 SR as a N-methyl-D-aspartate receptor antagonist and an AChE inhibitor, positions it as a third generation anti-Alzheimer's product by improving the general condition and cognitive functions of affected patients as well as having the potential of being a neuroprotectant. In addition, Debio 9902 SR once a month formulation aims to increase the benefit of the treatment by offering a better safety profile compared to already marketed AChE inhibitors, by increasing the compliance and -thus- the overall benefit for both the patients and their relatives.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts

Herve Porchet

VP, Medical Affairs

Tel.: +41-21-321-01-11

Fax: +41-21-321-01-69

hporchet@debiopharm.com

Emmanuel Tamches

Medical Director

Tel.: +41-21-321-01-11

Fax: +41-21-321-01-69

etamches@debiopharm.com

Additional Media Contacts

In London

Maitland

Brian Hudspith

Tel: +44-20-7379-5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Winnick Family Clinical Research Center Celebrates 6th Anniversary
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
4. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
5. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
6. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
7. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
8. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
9. Boston Scientific Announces Addition to Clinical Sciences Organization
10. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
11. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 WuXi Biologics, a leading open-access ... biologics and a WuXi AppTec Affiliate, today announced ... Bioprocessing Excellence Award from IMAPAC, a leading consulting ... to recognize outstanding leaders and trend-setters of today, ... and biomanufacturing experts in the industry, along with ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Agricultural Chelates ... over the next decade to reach approximately $825.4 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/29/2017)... India , March 29, 2017 The ... to 2022 report is a specialized and comprehensive study on the ... North America , Europe and ... Middle East and Africa ... Browse 172 ...
Breaking Biology Technology:
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
Breaking Biology News(10 mins):